JOURNAL OF CLINICAL SURGERY ›› 2025, Vol. 33 ›› Issue (10): 1091-1096.doi: 10.3969/j.issn.1005-6483.20241316

Previous Articles     Next Articles

Survival analysis of microsatellite instability and microsatellite stable right-sided colon cancer

LI Junchuan,LIU Hua,WEN Xiumei,ZHONG Xiaoqiong   

  1. Gastrointestinal Surgery,People's Hospital of Yanjiang District,Ziyang City,Ziyang 641300,China
  • Received:2024-08-05 Online:2025-11-11 Published:2025-11-11

Abstract: Objective Compare the clinicopathological factors of microsatellite unstable(dMMR) and microsatellite stable(pMMR) in right colon cancer and analyze the factors affecting overall survival(OS) and disease-free survival(DFS) between the two groups.Methods Clinical data with right colon cancer of patients who underwent radical resection from January 1,2016 to December 31,2023 were retrospectively analyzed(a total of 247 patients were included,including 43 dMMR and 204 pMMR).Through propensity score matching,the baseline difference between the two groups was matched 1∶1,and a total of 86 cases were obtained,43 cases in dMMR and 43 cases in pMMR.The difference of relevant indicators between the two groups was analyzed,and univariate and multivariate Cox analysis was performed for OS and DFS.The survival curve was plotted, and the comparison of survival rates was conducted using the Log-rank test.Results According to age,location,tumor length,shape,histological type,T,N,TNM stage,nerve invasion,and differentiation degree with 1∶1 matching(P<0.05),there was no statistical difference in baseline data between dMMR and pMMR patients with right colon cancer(P>0.05).It was found that 5-year OS of dMMR patients with right colon cancer was significantly better than pMMR(P<0.05),and 5-year DFS dMMR was better than pMMR(P<0.05).Protective factors affecting OS of dMMR right colon cancer included tumor length<5cm,T1-3,M0,Stage Ⅰ-Ⅲ,absence of intravascular cancer thrombi and absence of nerve invasion(P<0.05).In survival analysis,M0 was compared with M1(95% vs. 60%,P<0.05).Stage Ⅰ-Ⅲ compared with stage Ⅳ(95% vs. 54%,P<0.05);No vascular cancer thrombus vs. cancer thrombus(94% vs.88%,P<0.05).Protective factors affecting DFS of dMMR right colon cancer included age < 50 years,no mucous or sig-ring cells,M0,Stage Ⅰ-Ⅲ,and no intravascular cancer thrombus(P<0.05).In survival analysis,M0 was compared with M1(90% vs. 63%,P<0.05).Stage Ⅰ-Ⅲ compared with stage Ⅳ(92% vs. 57%,P<0.05);There was a significant difference between non-vascular cancer thrombus and vascular cancer thrombus(91%vs. 77%,P<0.05).Conclusion The patients with dMMR had higher OS and DFS than pMMR,which were not affected by clinical factors.

Key words: colon cancer, microsatellite instability, propensity score, overall survival, disease-free survival

[1] LI Shuping,WANG Lu,HU Shuna. Influence of general anesthesia induction with different doses of remimazolam on tracheal intubation stress response and hemodynamics in patients with radical resection of colon cancer [J]. JOURNAL OF CLINICAL SURGERY, 2025, 33(3): 306-309.
[2] QIN Le,HENG Yixin,XU Jiaxin,HUANG Ning,DENG Shenghe,GU Junnan,MAO Fuwei,XUE Yifan,JIANG Zhenxing,WANG Jun,CHENG Denglong,CAO Yinghao,CAI Kailin. Development and validation of a prognostic scoring system for colorectal cancer patients with Hepato-bone metastasis:a retrospective study [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(9): 947-954.
[3] HUANG Chao, FANG Xinggang, CHEN Lu. The impacts of serum miR-448 and miR-153 expression on intestinal microbiota and immune function in colon cancer patients [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(5): 506-510.
[4] WANG Shaoyi, NIE Kai, LI Ranran, CHEN Dafeng, XUE Xiaojun, YE Lei, LIU Jianping, ZHOU Song. Efficacy of XELOX regimen neoadjuvant chemotherapy in the treatment of stage Ⅱ(T4) and Ⅲ colon cancer [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(2): 188-191.
[5] QIAN Fang*,SHEN Haoyuan,DENG Chunyan,SU Tingting,HU Chaohua,LIU Chenghao,XU Yuanbing,YANG Qingqing. Effects of clinical treatment decisions on long-term survival outcomes of locally advanced breast cancer with different molecular subtypes based on the SEER database [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(10): 1044-1049.
[6] ZHAO Xin*,YIN Jian,JIA Tong. Effects of Nalbuphine on proliferation,apoptosis and epithelial mesenchymal transformation of colon cancer cells by regulating Hippo/YAP signaling pathway [J]. JOURNAL OF CLINICAL SURGERY, 2024, 32(10): 1100-1104.
[7] DING Huibin, ZHOU Hongfei. Comparison of the effect of combined midline approach and midline approach in laparoscopic D3 radical resection of right colon cancer [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(9): 869-872.
[8] LI Dawei, XIA Shihui. Influencing factors of disease-free survival in patients with stage Ⅲ non-small cell lung cancer after neoadjuvant chemotherapy combined with immunotherapy [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(7): 626-629.
[9] ZHOU Shuo, WANG Zhenjie, SUN Wanliang, et al. The correlation between CDH13 expression and clinical prognosis in elderly patients with colon cancer [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(2): 181-184.
[10] JI Shengwei, WANG Ping. Clinical value of microsatellite instability combined with tumor mutation load in evaluating postoperative recurrence and metastasis in NSCLC patients [J]. JOURNAL OF CLINICAL SURGERY, 2023, 31(11): 1065-1067.
[11] YIN Junfeng, GU Ming. The effect of circ_0007385 silence on the proliferation,migration and apoptosis of colon cancer cells [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(8): 762-766.
[12] LIU Shan, LIU Xin, LIN Yougang. Mechanisms of GATA3/GATA6 regulating autophagy and proliferation of colon cancer cell lines [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(7): 694-696.
[13] CHENG Liang, WU Xianfeng, ZHOU Encheng, et al. The expression of PTEN phosphorylation in gastric cancer and its correlation with clinicopathological characteristics and prognosis [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(4): 353-356.
[14] SHEN Jian, LI Minzhe, DU Yanfu. Effect of central obesity on clinical efficacy of laparoscopic D2 radical gastrectomy for distal gastric cancer [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(3): 261-265.
[15] ZHU Dongliang, LI Weihao, YAN Haidong, et al. Apatinib reduces the invasion ability of colon cancer cells and its molecular mechanism [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(2): 179-181.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!